← Eichor
Study identifier: NCT07656116 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors

Condition: Advanced Solid Tumor  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhasePhase 1
Planned participants27
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Yanjie Han, MD  ·  +86010-87788165  ·  annyhan_1997@163.com

Shuhang Wang, MD  ·  13581809307  ·  wangshuhang@cicams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical SciencLangfang, Hebei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07656116